Hycult Biotech/EPCR, Human, mAb RCR-252/HM2145/100 µg
商品编号：
HM2145
品牌：
hycultbiotech
市场价：
¥11304.00
美元价：
6782.40
产品分类：
单克隆抗体
公司分类：
monoclonal_antibody
联系Q Q：
3392242852
电话号码：
4000-520-616
电子邮箱：
info@ebiomall.com
商品介绍
Description:EPCR,Human,mAbRCR-252
ThemonoclonalantibodyRCR-252recognizeshumanendothelialproteinCreceptor(EPCR),ahighlyglycosylatedtypeItransmembraneproteinof221-amino-acids.Theseaminoacidscompriseanextracellulardomain,a25-aatransmembranedomain,andashort(3aa)intracytoplasmicsequencecodingforan~46kDaprotein.Deglycosylationwillreducetheproteinmassto25kDa.EPCRisexpressedstronglyontheendothelialcellsofarteriesandveinsinheartandlung,lessintenselyincapillariesinthelungandskin,andnotatallintheendotheliumofsmallvesselsoftheliverandkidney.
EPCRisthereceptorforproteinC,akeyplayerintheanticoagulationpathway.TheproteinCanticoagulantpathwayservesasamajorsystemforcontrolingthrombosis,limitinginflammatoryresponses,andpotentiallydecreasingendothelialcellapoptosisinresponsetoinflammatorycytokinesandischemia.Theessentialcomponentsofthepathwayincludethrombin,thrombomodulin,theendothelialcellproteinCreceptor(EPCR),proteinCandproteinS.Thepathwayisinitiatedwhenthrombinbindstothrombomodulinonthesurfaceofendothelium.EPCRaugmentsproteinCactivationbybindingproteinCandpresentingittothethrombin-thrombomodulinactivationcomplex.ActivatedproteinC(aPC)retainsitsABIlitytobindEPCR,andthiscomplexappearstobeinvolvedinsomeofthecellularsignalingmechanismsthatdown-regulateinflammatorycytokineformation(TNF,IL-6).EPCRisshedfromthevasculaturebyinflammatorymediatorsandthrombin.EPCRbindstoactivatedneutrophilsinaprocessthatinvolvesproteinase3andMac-1.FurThermore,EPCRcanundergotranslocationfromtheplasmamembranetothenucleus.
EPCRcanbecleavedtoreleaseasolubleform(sEPCR)inthecirculation.ThissEPCRisdetectedasasinglespeciesof43kDa,resultingfromsheddingofmembraneEPCRbytheactionofametalloprotease,-whichisstimulatedbythrombinandbysomeinflammatorymediators.SolubleEPCRbindsPCandaPCwithsimilaraffinity,butitsbindingtoaPCinhibitstheanticoagulantactivityofaPCbyblockingitsbindingtophospholipidsandbyabrogatingitsabilitytoinactivatefactorVa.sEPCR-canbedetectedinplasma.Innormalpersons,sEPCRispresentinlevelsof83.6+/-17.2ng/ml.ElevatedlevelsofsEPCRarepositivelycorrelatedtoahigherriskforthrombosis.Furthermore,ahaplotype(A3allele)hasbeenlinkedtoelevatedlevelsofsEPCR(264+/-174ng/ml).
EPCRisthereceptorforproteinC,akeyplayerintheanticoagulationpathway.TheproteinCanticoagulantpathwayservesasamajorsystemforcontrolingthrombosis,limitinginflammatoryresponses,andpotentiallydecreasingendothelialcellapoptosisinresponsetoinflammatorycytokinesandischemia.Theessentialcomponentsofthepathwayincludethrombin,thrombomodulin,theendothelialcellproteinCreceptor(EPCR),proteinCandproteinS.Thepathwayisinitiatedwhenthrombinbindstothrombomodulinonthesurfaceofendothelium.EPCRaugmentsproteinCactivationbybindingproteinCandpresentingittothethrombin-thrombomodulinactivationcomplex.ActivatedproteinC(aPC)retainsitsABIlitytobindEPCR,andthiscomplexappearstobeinvolvedinsomeofthecellularsignalingmechanismsthatdown-regulateinflammatorycytokineformation(TNF,IL-6).EPCRisshedfromthevasculaturebyinflammatorymediatorsandthrombin.EPCRbindstoactivatedneutrophilsinaprocessthatinvolvesproteinase3andMac-1.FurThermore,EPCRcanundergotranslocationfromtheplasmamembranetothenucleus.
EPCRcanbecleavedtoreleaseasolubleform(sEPCR)inthecirculation.ThissEPCRisdetectedasasinglespeciesof43kDa,resultingfromsheddingofmembraneEPCRbytheactionofametalloprotease,-whichisstimulatedbythrombinandbysomeinflammatorymediators.SolubleEPCRbindsPCandaPCwithsimilaraffinity,butitsbindingtoaPCinhibitstheanticoagulantactivityofaPCbyblockingitsbindingtophospholipidsandbyabrogatingitsabilitytoinactivatefactorVa.sEPCR-canbedetectedinplasma.Innormalpersons,sEPCRispresentinlevelsof83.6+/-17.2ng/ml.ElevatedlevelsofsEPCRarepositivelycorrelatedtoahigherriskforthrombosis.Furthermore,ahaplotype(A3allele)hasbeenlinkedtoelevatedlevelsofsEPCR(264+/-174ng/ml).
Specifications:
| Catalognumber | HM2145 |
|---|---|
| Producttype | Monoclonalantibodies |
| Quantity | 100µg |
| Formulation | 1ml(100μg/ml)0.2μmfilteredproteinGpurifiedantibodysolutioninPBS,containing0.1%bovineserum. |
| Application | Flowcytometry,Functionalstudies,Immunoprecipitation,Westernblot |
| ApplicationNotes | FC:AntibodyRCR-252stainstheextracellulardomainofhumanEPCR.AspositivecontrolRE-1cellswereusedandasnegativecontrolN1cells.(Ref.1) W:Anon-reducedsampletreatmentwasused.Theobservedbandsizeis50kDa(Ref.5). FS:AntibodyRCR-252functionsasblockingantbody.ItablatesAPCbindingtoEPCRandblocksAPC-mediatedsignaling.Theantibodywasfunctionallytestedbypretreatmentofcellswith10-25 µg/mlRCR-252(Ref.1-4). |
| Use | Dilutionstobeuseddependondetectionsystemapplied.Itisrecommendedthatuserstestthereagentanddeterminetheirownoptimaldilutions.Thetypicalstartingworkingdilutionis1:50. |
| Immunogen | HumanEPCR-positiveRE-1cells |
| Isotype | RatIgG1 |
| Species | Human |
| Alias | ActivatedproteinCreceptor,CD201,EndothelialcellproteinCreceptor Genename:PROCR |
| PositiveControl | RE-1(rat3Y1fibroblastsstablytransfectedwithhumanEPCR. |
| NegativeControl | N1cells |
| References | 1.Ye,Xetal;TheendothelialcellproteinCreceptor(EPCR)functionsasaprimaryreceptorforproteinCactivationonendothelialcellsinarteries,veins,andcapillaries.BiochemBiophysResCommun1999,259:671 2.Dömötör,Eetal;ActivatedproteinCalterscytosoliccalciumfluxinhumanbrainendotheliumviabindingtoendothelialproteinCreceptorandactivationofproteaseactivatedreceptor-1.Blood2003,101:4797 3.Sturn,Detal;ExpressionandfunctionoftheendothelialproteinCreceptorinhumanneutrophils.Blood2003,102:1499 4.Finigan,Jetal;ActivatedproteinCmediatesnovellungendothelialbarriereenhancement.JBiolChem2005,280:17286 5.BaeJetal;ReceptorsoftheproteinCactivationandactivatedproteinCsignalingpathwaysarecolocalizedinlipidraftsofendothelialcells.PNAS2006,104:2867 |
| Storageandstability | Productshouldbestoredat4 °C.Underrecommendedstorageconditions,productisstableforoneyear. |
| Precautions | Forresearchuseonly.Notforuseinoronhumansoranimalsorfordiagnostics.Itistheresponsibilityoftheusertocomplywithalllocal/stateandFederalrulesintheuseofthisproduct.HycultBiotechisnotresponsIBLeforanypatentinfringementsthatmightresultwiththeuseoforderivationofthisproduct. |
| Disease | Cardiologyandmetabolism |
品牌介绍
荷兰HyCult Biotechnology(HBT)位于荷兰乌登，从1994开始制造检测抗体和蛋白质，主要侧重与病理学诊断有关的全套产品研发，既有纯化的重组蛋白和多肽，也有单抗和多抗，是世界一流的先天免疫领域的研究试剂制造商。
联络我们
